Comparative Efficacy of Ribosome-Inactivating Protein-Containing Immunotoxins in 2D and 3D Models of Sarcoma
Toxins · 18.06.2025 · 17 (6) · 308
DOI: 10.3390/toxins17060308 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Toxins, online erschienen am 18.06.2025. Verfasst von Giulia Calafato und 3 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy. Hauptthemen laut MEDLINE: Immunotoxins, Ribosome Inactivating Proteins, Sarcoma, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alma Mater Studiorum, University of Bologna, Pallotti Legacies for Cancer Research.
Abstract (Originalsprache)
Sarcomas are very complex and clinically challenging mesenchymal tumors. Although the standard therapeutic approach has improved the 5-year survival rate, many patients experience local relapses and/or distant metastases. To improve patient outcome, new strategies need to be investigated. Immunotoxins (ITs) based on rRNA N-glycosylases (also named ribosome-inactivating proteins, RIPs) are promising tools for cancer therapy because, by combining rRNA-glycosylase’s high cytotoxicity with carrier selectivity, they can specifically eliminate target neoplastic cells. In the last few years, 3D models have been extensively used in cancer research, particularly for target-specific drug screening. This study aimed to evaluate the possibility of utilizing ribosome-inactivating protein (RIP)-containing ITs to selectively target TfR1-, EGFR1- and Her2-expressing sarcoma adherent cells (ACs), spheroids (SSs) and organoids (ORs). To compare Its’ efficacy and ability to induce apoptosis, we performed dose–response viability and caspase 3/7 activation assays on rhabdomyosarcoma and osteosarcoma ACs, SSs and ORs treated with Tf-IT, αEGFR1-IT and αHer2-IT. Our results indicate that, compared to the corresponding unconjugated RIPs, all ITs showed increased cytotoxicity in sarcoma ACs. Despite the increased complexity characterizing 3D models, the higher IC50 differences between ITs and unconjugated RIPs were obtained in ORs, which appeared more resistant to the nonspecific killing of the RIPs than either the ACs or SSs, thus augmenting the therapeutic window between unconjugated and conjugated RIPs. IT induced a more delayed apoptosis in 3D compared to 2D models. Our results provide essential outcomes for the potential use of these RIP-based ITs as a therapeutic strategy to treat sarcoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
- Department of Medical and Surgical Sciences-DIMEC, Alma Mater Studiorum, University of Bologna, 40126 Bologna, Italy.
ORCID-Profile: Giulia Calafato, Massimo Bortolotti, Letizia Polito, Andrea Bolognesi
Förderung
- Alma Mater Studiorum, University of Bologna
- Pallotti Legacies for Cancer Research
Zitieren
APA
Calafato, G., Bortolotti, M., Polito, L., & Bolognesi, A. (2025). Comparative Efficacy of Ribosome-Inactivating Protein-Containing Immunotoxins in 2D and 3D Models of Sarcoma. Toxins, 17(6), 308. https://doi.org/10.3390/toxins17060308
Vancouver
Calafato G, Bortolotti M, Polito L, Bolognesi A. Comparative Efficacy of Ribosome-Inactivating Protein-Containing Immunotoxins in 2D and 3D Models of Sarcoma. Toxins. 2025;17(6):308. doi:10.3390/toxins17060308
BibTeX
@article{Calafato2025,
author = {Calafato, Giulia and Bortolotti, Massimo and Polito, Letizia and Bolognesi, Andrea},
title = {Comparative Efficacy of Ribosome-Inactivating Protein-Containing Immunotoxins in 2D and 3D Models of Sarcoma},
journal = {Toxins},
year = {2025},
volume = {17},
number = {6},
pages = {308},
doi = {10.3390/toxins17060308}
}
EUVIMED